MGNX News and Press, MacroGenics Inc. From 09/12/22

MacroGenics (NASDAQ: MGNX) investors were suffering from a case of the Mondays, as their stock lost more than 8% of its value on the day. That compared rather unfavorably to the more than 1% gain of the S&P 500 index. MacroGenics' decline came about because of a fresh price ...

Famed hedge fund manager Israel "Izzy" Englander and his Millennium Management fund revealed a 5.2% stake in MacroGenics ( NASDAQ: MGNX ), sending shares of the small-cap biopharmaceutical company up 6.4% after hours on Friday. The passive stake was disclosed in a 13...

Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q2 2022 Earnings Call Aug 08, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q2 2022 Earnings Call Transcript

MacroGenics, Inc. (MGNX) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Chris James - VP, IR and Corporate Communications Scott Koenig - President and CEO Jim Karrels - CFO Conference Call Participants Jon Miller - E...

MacroGenics press release ( NASDAQ: MGNX ): Q2 GAAP EPS of -$0.67 beats by $0.30 . Revenue of $26.01M (-15.4% Y/Y) beats by $11.91M . Shares -1.1% . For further details see: MacroGenics GAAP EPS of -$0.67 beats by $0.30, revenue of $26.01M beats b...

First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies Plan to initiate MGC018 Phase 2/3 study in prostate cancer by year-end Initiates cost-saving measures through corporate restructuring with focus on key clinical programs, extending ...

Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...

MacroGenics ( NASDAQ: MGNX ) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.97 and the consensus Revenue Estimate is $14.1M (-54.2% Y/Y). Over the last 3 months, EPS estimates have seen 2 upwa...

ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...

Shares of micro-cap company MacroGenics ( NASDAQ: MGNX ) fell ~19% to $3.41 in Monday trading, as a rating downgrade by SMBC Nikko Securities weighed on the stock. SMBC Nikko lowered its rating on MGNX to neutral from outperform, citing the halt of the company's mid-stag...